KRICT

FOXM1 저해제인 대장암 치료제 개발

Korea Research Institute of Chemical Technology

Contact (Licensing)

- Shin Hei Choi(Head), shchoi@krict.re.kr, 042-860-7192
- Kyung Sun Choi, chanian@krict.re.kr, 042-860-7076

Target	FOXM1

기술개요







FoxM1
- oncogenic transcription factor
- important role in cancer drug resistance
- association with poor prognosis
- low expression in normal tissue

Biochem. Biophys. Acta. **2012**, *1819*, 28.
Clin. Cancer Res. **2013**, *19*, 62.

주요성과



- siRNA: cancer cell viability, mRNA level
- assay system
  - binding: TR-FRET, SPR, EMSA
  - cell viability: CCK, 3D-spheroid

향후계획

- 선도물질 도출
- 공동연구 추진

KRICT

FOXM1 저해제인 대장암 치료제 개발

Korea Research Institute of Chemical Technology

Contact (Science)	• Sung-Youn Chang, Ph.D, sychang@krict.re.kr, 042-860-7161)

Target	Target Name
Mechanism of Action	• Inhibition of FOXM1-DNA interaction by small molecule
Indication - Primary	• Colorectal cancer
Indication - Expansion	• Breast, prostate, lung, and brain cancer, leukemia
Route of Administration	• PO
Competitive Advantage	• First-in-class • Drug targeting cancer stem cell • Targeting patients with drug resistance
Data Files	• siFoxM1: cancer cell viability, target mRNA level • in vitro data with small molecules: TR-FRET, EMSA, SPR, cancer cell viability
IP Status	• not yet
Collaboration Model	• collaborative research